+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Arginine Vasopressin Is a Much More Potent Stimulus to ACTH Release from Ovine Anterior Pituitary Cells than Ovine Corticotropin-Releasing Factor

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Cultured rat and ovine anterior pituitary cells were treated with a range of doses (0.01–1,000 n M) of arginine vasopressin (AVP) and ovine corticotropin-releasing factor (CRF), alone or in combination, and medium and cell content of immunoreactive (ir-)ACTH determined. In rat cells, a dose-response curve to CRF was obtained, with a threshold dose of 0.1 n M; AVP was much less effective alone, but augmented CRF responses when administered with CRF. In ovine pituitary cells AVP markedly stimulated ACTH release in a dose-dependent fashion, and with a threshold of 0.1 n M; in contrast, CRF increased ACTH release over basal only at doses > 100 n M. In combination, subthreshold doses of AVP potentiated rat pituitary cell responses to CRF; addition of 1 n M of AVP to varying doses of CRF was more effective in terms of ACTH release than addition of 1 n M of CRF to increasing doses of AVP. In contrast, in ovine cells the addition of 1 n M CRF to increasing doses of AVP elicited a larger ACTH response than the addition of 1 n M AVP to increasing doses of CRF. Dexamethasone pretreatment (5 n M) for 48 h significantly decreased CRF potentiation of AVP-stimulated ACTH release in ovine cells. These studies confirm that CRF is a more potent stimulus of ACTH release than AVP in the rat, and establish that in contrast AVP is a much more potent stimulus of ACTH secretion than CRF in isolated ovine pituitary cells.

          Related collections

          Author and article information

          S. Karger AG
          02 April 2008
          : 50
          : 2
          : 152-157
          Medical Research Centre, Prince Henry’s Hospital, Melbourne, Australia
          125214 Neuroendocrinology 1989;50:152–157
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article